Fusion polypeptides

US6423512B1 · kind B1 · utility

Assignee

• Novartis AG · CH

Inventors

• Mary Ellen Digan · Winchester, US
• Philip Lake · Parsippany, US
• Hermann Gram · Weil am Rhein, DE

Key dates

• Filing date: Jul 21, 1997
• Grant date: Jul 23, 2002
• Expiry date: Jul 21, 2017

Classification

• Technology area (CPC Y): Emerging Cross-Sectional Technologies
• CPC primary: Y10S530/868
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Fusion polypeptides and salts thereof comprising at least one IgE-binding domain fused to at least one human serum albumin component, optionally via a peptide linker, and in particular, dimeric fusion polypeptides comprising HSA protein fused, at each of its amino and carboxy termini, to an extracellular domain of the &agr;-chain of the human high affinity receptor for IgE (Fc&egr;RI&agr;); process for the preparation thereof, functionally equivalent polypeptides which are intermediates in their preparation, and polynucleotide and oligonucleotide intermediates and vectors therefor. They are indicated for use in the prevention and/or treatment of IgE-mediated allergic diseases and related disorders such as atopic dermatitis, atopic asthma and chronic urticaria.